The present work describes the development and validation of a simple, rapid, selective and reproducible RP-HPLC method for the Analysis of Tadalafil in Bulk, tablets and In-Vitro Dissolution Samples. Analysis was performed on an Agilent, EclipseC18 column (150 mm × 4.6 mm, 5 m) with the mobile phase consisting of ammonium acetate (10 mM):methanol (35:65v/v) at a flow rate of 1.0 mL/min. UV detection was performed at 280 nm and the retention time for TDL was 4.6 minutes. The dissolution media composed of 0.5% SLS, using USP II (Paddle) Dissolution apparatus, at 50 RPM and temperature maintained 37.0 ± 0.5 ͦ C. The method was validated according to ICH guidelines. The method was validated for specificity, accuracy, precision, ruggedness, limit of quantification, limit of detection and linearity. The system suitability parameters, such as , tailing factor, theoretical plate and relative standard deviation (RSD) for assay of five standard replicates, were well within the limits. The results of the studies showed that the proposed RP-HPLC method is simple, rapid, precise and accurate. Hence the method can be used for the routine Dissolution Profiling of Tadalafil as well as its assay in bulk and tablets .
INTRODUCTION
Tadalafil [(TDL) Figure 1 ] is used to treat male erectile dysfunction. TDL belongs to phosphordieterase type-5 inhibitor (PDE5) class (Sweetman, 2002) . It inhibits cGMP specific PDE5 which is responsible for degradation of cGMP in the corpus cavernosum located around the penis. In order to prevent the malpractices of Counterfeiting drugs that has now become a multi-billion dollar business that threatens the well being of the humanity and effective delivery of health care services (Abdulmumin, 2011) and to ensure quality of drugs; simple, sensitive and selective methods for their QC analysis are indispensible. Dissolution studies and Assays are routinely performed in Quality Control (QC) and R&D Laboratories for the evaluation of pharmaceutical products (Azarmi et al., 2012) .
. Vijayawada, AP, India. Email: mail id: khushiazeez@yahoo.co.in The literature review showed a few HPLC methods for estimation of TDL individually (Sankar and Arulantony, 2013; Sonawane et al., 2013; ) or in combination with other drugs like Sildenafil citrate (Kannapan et al., 2010) and Dapoxetine hydrochloride (Abha et al., 2012 ; Bharat et al., 2013) , LC-MS (Xiaolan Zhu et al., 2005) , UVVisible Spectrophotometry (Mohammad et al., 2010 , Safwan, 2014 and Flourimetry (Kavitha et al., 2013) methods were reported so far. However there is no RP-HPLC estimation for dissolution profiling of TDL.
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All the reported methods either took a long time for analysis or employed mobile phases with pH adjustment of buffer solutions which is tedious and not suitable, particularly for routine testing of tablet and dissolution samples.
Hence, an attempt was made to develop a rapid, simple, accurate and reproducible and LC-MS compatible RP-HPLC-PDA method for the estimation of TDL in tablet dosage forms and in dissolution samples to support product development and quality control efforts. 
MATERIALS AND METHODS

Materials
TDL pure drug was gift sample obtain from Macleodes, India. HPLC Grade Ammonium Acetate and Methanol were procured from E. Merck Ltd, India. Sodium Lauryl Sulphate was purchased from Loba Chemie, Mumbai, India.0.45-μm nylon filters were purchased from Advanced Micro Devices Pvt. Ltd. India. Mili-Q water was used throughout the experiment. Megalis-10 mgtablets were purchased from local pharmacy.
Instrumentation
Analysis was performed on a Shimadzu HPLC chromatographic system, class VP series (Japan) equipped with SIL-20A auto sampler, programmable variable wavelength PDA detector SPD-M20A VP and two LC-20AD pumps. Chromatographic separation was achieved by Agilent eclipse C 18 column (150×4.6 mm, 5 µm). The HPLC system was equipped with "LC-Solution" software to acquire and process the data. Peak purity was checked with the PDA detector. All dissolution studies were carried out using Dissolution test apparatus (DISSO 8000, Lab India).
METHODOLOGY
Dissolution studies
In vitro dissolution studies of TDL tablets was carried out in 900mL of 0.5% SLS using USP type-II (paddle) Dissolution test apparatus. The tablet was directly placed in the dissolution medium. A speed of 50 rpm and a temperature of 37±0.5°C were used in the test. A 5mL aliquot was withdrawn at 10, 15, 20, 30 and 45 min and replaced with 5mL of fresh dissolution medium. The samples were filtered using 0.45µm nylon disc filter, suitably diluted if necessary and analysed by HPLC. The dissolution experiments were conducted in triplicate. The amount of TDL in the test samples was calculated as percentage drug dissolved, by comparing peak area of the test samples with standard.
Standard solutions and calibration plots
Accurately weighed amount of standard TDL bulk (10 mg) was transferred to a 10 mL volumetric flask containing few mL of MeOH, the solution was sonicated for 2min and volume was made up to the mark with the same solvent to obtain final concentration of 1mg/mL. Aliquots of above stock solution containing 5 to 25 µg of drug were transferred in to a series of centrifuge tubes and the volume was made up to 1 mL using ammonium acetate. 20 µL of standard at each concentration level was injected into the column in triplicate. The mean values of peak areas were plotted against concentrations.
Liquid chromatographic conditions
An isocratic HPLC analysis was performed on Agilent, EclipseC18 column (150 mm × 4.6 mm, 5 m)maintained at ambient conditions (37 ± 0.5 0 C).Chromatographic separation was achieved with the mobile phase ratio of 35:65 (v/v) mixture of 10 mM ammonium acetate and MeOH at flow rate of 1.0ml/min and injection volume of 20 µL. UV spectra of TDL (10 µg/mL) was scanned under these conditions and from the spectra a maxima of 280 nm was observed ( Figure 2 ). For quantitative analytical purpose wavelength was set at 280 nm, which also provided a better reproducibility. 
Method validation Specificity
Placebo solution was prepared as that of the test solution using equivalent weight of the placebo in a portion. The diluent, placebo, pure drug and sample solution were injected into the HPLC system following the test conditions, the chromatograms were recorded for each of the solutions and the response of the peaks were noted for examining interference.
Linearity
The Linearity was established at the concentration range of 5-25 µg/mL for TDL. The standard stock solution (1000 µg/mL) was diluted with MeOH to get standard solutions in the range of 5-25 µg/mL TDL. Each concentration was analyzed in triplicate. Peak areas (y) of TDL were plotted versus their respective concentrations (x), linear regression analysis performed on the resultant calibration curves and correlation coefficient (R) was calculated.
System suitability
System suitability was carried out by injecting 10g/mL of Tadalafil at different injection volumes ranging from 10 to 50 µL. The % RSD values for tailing factor and theoretical plates were calculated and the data given in Table 1 . 
Accuracy/recovery
Accuracy is the measure of closeness the experim ental value to it's the true value. It should be established across the specified range of the analytical procedure. To confirm the accuracy of the proposed method recovery studies were performed by spiking 80% (8 µL), 100% (10 µL) and 120% (12 µL) of the standard to the synthetic solution of drug product.
Limit of detection and quantification
LOD and LOQ were determined based on statistical calculation from the calibration curves, where LOD = (3.3 ×σ)/m; LOQ= (10.0×σ)/m ( is the standard deviation of the y-intercepts of the three regression lines and m is mean of the slopes of the three calibration curves).
Precision
Precision was determined in terms of repeatability of application (System precision) and measurement (Method precision). The precision of the method was ascertained from the peak areas of six replicate injections of a fixed standard concentration.
Repeatability of standard application was assessed by using six replicates of concentration at 10µg/mL level. The standard deviation and the relative standard deviation were computed for precision.
Robustness
Robustness of the proposed method was determined by analyzing the standard solution at normal operating conditions and by deliberately changing some of the conditions such as flow rate, column, oven temperature, detection wavelength and the mobile phase.
Assay of the formulation
Randomly picked twenty tablets were weighed individually and finely powdered. A powder blend equivalent to 10 mg of TDL was transferred to a 10 mL volumetric flask containing about 5mL of methanol, sonicated and made up with the same solvent. The solution was filtered through 0.45 μm nylon membrane filter to obtain a stock solution of 1mg/mL. It was further diluted with diluent to get the required concentration (10 μg/mL of TDL). The solution was injected three times into the column.
RESULTS AND DISCUSSIONS
Method development and optimization
In order to optimize the LC conditions for the estimation of TDL in bulk, tablets and in vitro dissolution samples analysis, the following trials were performed. Initially a mobile phase consisting of Water: Methanol (50:50 %v/v) at a flow rate of 1.0 mL/min was used on an Agilent Eclipse C 18 column (150 x 4.6 mm, 5) column at ambient temperature using methanol as a diluent, TDL did not elute under these conditions. In the next trial, same column was employed but the mobile phase was changed to ammonium acetate and methanol (50:50 v/v), TDL eluted at retention time of 2.84 min but peak parameters were not observed optimal (tailing factor >2). To obtain better peak properties diluents was switched to 10 mM ammonium acetate, TDL eluted with good symmetry and peak properties (tailing factor-1.102) at a retention time of 6.38. In order to further optimize the retention time of TDL, the percentage of organic modifier, methanol was increased and a mobile phase composition of 10 mM Ammonium acetate: Acetonitrile (70:30% v/v), the peak eluted at 0.63 min. Finally 10 mM Ammonium acetate: Methanol (35:65% v/v) was used as mobile phase and a symmetrical peak was observed at the retention time of 4.56 min.
Method validation Specificity
From the base shift ovelay of the chromatograms in (Figure 3 ) and 3D plots of diluents, standard, placebo and formulation shown in (Figure 4) , it can be inferred that there were no co eluting interfering peaks with the drug peaks ( Figure 5 ). 
Linearity
The Linearity was established at the concentration range of 5-25 µg/mL for TDL. Peak areas (y) of TDL were plotted versus their respective concentrations (x) and linear regression analysis performed on the resultant calibration curves. Linearity data was shown in Table 1 and Figure 6 . Calibration curve depicted in figure 7. 
System suitability
The RSD values for system suitability test parameters like retention time [R t = 4.6262 (1.0207%)], tailing factor [T f = 1.0826 (0.2224 %)] and theoretical plate number [5259.115 (1.7864 %)] were found to be less than 2 % indicating the present conditions were suitable for the analysis of TDL in tablets. The overlay chromatogram of system suitability is given Figure 8 .
Accuracy
The recovery of the standard added to the drug product sample was calculated and it was found to be 99.26-100.97 %. The % RSD was less than 2. The data was given in Table 2 . Limit of detection and quantification LOD and LOQ for TDL were determined according to ICH guideline Q2 (R1) . LOD and LOQ were found to be 0.009g/mL and 0.0272g/mL respectively, indicating good sensitivity of the method.
Precision
System precision and method precision was confirmed as the % RSD were well within the target criterion (<2%). Precision data was shown in Table 3 and Figure 9 . 
Robustness
Robustness of the method was determined by analyzing the standard solution at normal operating conditions and by changing some of the conditions. The conditions varied and their results were shown in Table 4 . The tailing factor is below 2 which is acceptable. Assay of the marketed formulation Assay of TDL tablets was performed by the proposed method and the % assay of the formulation was calculated as an average of 3 determinations. The data is given in table 5. The assay was found to be within the limits, indicating that the present LC conditions can be used for the assay of TDL in different commercially available formulations. 
Dissolution studies
The dissolution experiments were conducted in triplicate as per the method described above. The amount of TDL in the test samples was calculated as percentage drug dissolved, by comparing peak area of the test samples with standard. The dissolution parameters and data for 6 tablets were given in table 6 and 7. The dissolution profile was depicted in figure 10. Filter compatibility study Compatibility of 0.45µm nylon filter and 0.45µm PVDF filter was studied. Standard sample solution and dissolution samples were filtered and analysed and the variation in the assay value was calculated and tabulated in Table 8 . After the analysis it was found that nylon filters are suitable for filtration. 
CONCLUSION
The simple, rapid, sensitive, and inexpensive isocratic RP-HPLC method was developed and validated for the estimation of TDL in bulk and pharmaceutical formulation and dissolution samples. The dissolution study showed that TDL has good stability and the percentage of drug released was satisfactory for all the evaluated batches from the formulation. The method was in compliance with all validation parameters. Therefore this method is proposed for the quality control of TDL in bulk and its pharmaceutical dosage forms contributing to assuring the therapeutic efficacy of the drug.
